Merck & Co., Inc. (MRK) research: valuation against peers, fundamentals over time, risk and news coverage
ChartVs peersValuationValue mapQuartersScaleMarginsTrajectoryCash qualityPer shareReinvestmentBalance sheetStreetRiskSeasonalityOur coverage
MRK
Merck & Co., Inc.USD
142.79
+0.60% today
Market cap
—
P/E trailing
—
P/E forward
—
EV/EBITDA
—
Op margin
—
Rev growth
—
Div yield
—
Beta
—
Price navigator — MRK
No data in this window.
INDY NEWS coverage of MRK1
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBEARISHInsider Distribution Broadens Across Healthcare and Tech as Buying Narrows to Small-Cap Value
A cluster of Form 4 filings shows concentrated executive selling: Merck EVP DeLuca disposed of $5.9 million, Corcept's chief development officer sold $1.8 million, Twilio director Erika Rottenberg sold $881,000, and A10 Networks' general counsel sold $392,435. Avalo Therapeutics saw both its CMO and CSO reduce stakes. Insider buying was materially smaller and concentrated in value names, with Celanese SVP Murray purchasing $98,004 and Biote executive chairman Marc Beer acquiring over $202,000. Cathie Wood's ARK also trimmed $11.6 million from a surging tech position.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.
Guidance reliability · MRKmethodology·all companies
Only 3 resolved forecasts on record — below the 6-period threshold, so no verdict is published.
n = 3 resolved forecasts · FY 2023 to FY 2023 · 11 still outstanding
Insufficient sample — no verdict published. MRK has 3 resolved forecasts on record, below the 6 needed before we will characterise a management team’s forecasting. The record below is published in full; the company is excluded from every ranking on this site until it clears the threshold.
Pattern
Not enough resolved periods
3 resolved
Avg. signed deviation
−57.3%
outside its own range
Avg. vs midpoint
−57.6%
where in the range it lands
Avg. range width
1.9%
room it leaves itself
Above guidance1Below guidance2
Next report expected 29 Oct 2026 (Q3 FY2026) — Estimated from the issuer's own filing history: FY2025Q3 results were released on 2025-10-30. source
The record — 44 forecasts, 14 scoredevery figure sourced
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2026revised | EPS (adj.) | $2.66–$2.76 | 2026-08-04 | — | — | — | PENDING | guidance |
| “The Company now expects full-year 2026 non-GAAP EPS to be between $2.66 and $2.76, including a positive impact from foreign exchange of approximately $0.15 per share at mid-July 2026 exchange rates.” | ||||||||
| FY 2026revised | Revenue | $66.30–$67.30bn | 2026-08-04 | — | — | — | PENDING | guidance |
| “The Company is raising and narrowing the range for its full-year sales outlook and now anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion, including a positive impact from foreign exchange of approximately 1% at mid-July 2026 exchange rates.” | ||||||||
| FY 2026revised | EPS (adj.) | $5.04–$5.16 | 2026-04-30 | — | — | — | PENDING | guidance |
| “The Company now expects full-year 2026 non-GAAP EPS to be between $5.04 and $5.16, including a positive impact from foreign exchange of approximately $0.10 per share at mid-April 2026 exchange rates.” | ||||||||
| FY 2026revised | Revenue | $65.80–$67.00bn | 2026-04-30 | — | — | — | PENDING | guidance |
| “The Company now anticipates full-year 2026 sales to be between $65.8 billion and $67.0 billion, including a positive impact from foreign exchange of approximately 1% at mid-April 2026 exchange rates.” | ||||||||
| FY 2026 | EPS (adj.) | $5.00–$5.15 | 2026-02-03 | — | — | — | PENDING | guidance |
| “The Company expects full-year 2026 non-GAAP EPS to be between $5.00 and $5.15, including a positive impact from foreign exchange of approximately $0.10 per share at mid-January 2026 exchange rates.” | ||||||||
| FY 2026 | Revenue | $65.50–$67.00bn | 2026-02-03 | — | — | — | PENDING | guidance |
| “The Company anticipates full-year 2026 sales to be between $65.5 billion and $67.0 billion, including a positive impact from foreign exchange of approximately 1% at mid-January 2026 exchange rates.” | ||||||||
| FY 2025revised | EPS (adj.) | $8.93–$8.98 | 2025-10-30 | — | — | — | PENDING | guidance |
| “The Company now expects its full-year non-GAAP EPS to be between $8.93 and $8.98, including a negative impact of foreign exchange of approximately $0.15 per share.” | ||||||||
| FY 2025revised | Revenue | $64.50–$65.00bn | 2025-10-30 | — | — | — | PENDING | guidance |
| “The Company now expects full-year 2025 sales to be between $64.5 billion and $65.0 billion, including a negative impact of foreign exchange of approximately 0.5% at mid-October 2025 exchange rates.” | ||||||||
| FY 2025revised | EPS (adj.) | $8.87–$8.97 | 2025-07-29 | — | — | — | PENDING | guidance |
| “Narrows Expected Non-GAAP EPS Range To Be Between $8.87 and $8.97” | ||||||||
| FY 2025revised | Revenue | $64.30–$65.30bn | 2025-07-29 | — | — | — | PENDING | guidance |
| “Narrows Expected Worldwide Sales Range To Be Between $64.3 Billion and $65.3 Billion” | ||||||||
| FY 2025revised | EPS (adj.) | $8.82–$8.97 | 2025-04-24 | — | — | — | PENDING | guidance |
| “Merck now expects its full-year non-GAAP EPS to be between $8.82 and $8.97, including a negative impact of foreign exchange of more than $0.20 per share.” | ||||||||
| FY 2025revised | Revenue | $64.10–$65.60bn | 2025-04-24 | — | — | — | PENDING | guidance |
| “Continues To Expect Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion” | ||||||||
| FY 2025 | EPS (adj.) | $8.88–$9.03 | 2025-02-04 | — | — | — | PENDING | guidance |
| “Expects Non-GAAP EPS To Be Between $8.88 and $9.03; Outlook Reflects a One-Time Charge of Approximately $0.09 per Share Related to an Anticipated Milestone Payment to LaNova” | ||||||||
| FY 2025 | Revenue | $64.10–$65.60bn | 2025-02-04 | — | — | — | PENDING | guidance |
| “Anticipates Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion” | ||||||||
| FY 2024revised | EPS (adj.) | $7.72–$7.77 | 2024-10-31 | — | — | — | PENDING | guidance |
| “Merck now expects its full-year non-GAAP EPS to be between $7.72 and $7.77.” | ||||||||
| FY 2024revised | Revenue | $63.60–$64.10bn | 2024-10-31 | — | — | — | PENDING | guidance |
| “Merck now expects its full-year sales to be between $63.6 billion and $64.1 billion, including a negative impact of foreign exchange of approximately 3 percentage points, at mid-October 2024 exchange rates.” | ||||||||
| FY 2024revised | EPS (adj.) | $7.94–$8.04 | 2024-07-30 | — | — | — | PENDING | guidance |
| “Merck now expects its full-year non-GAAP EPS to be between $7.94 and $8.04, including one-time charges of $0.26 and $0.51 per share for the acquisitions of Harpoon and EyeBio, respectively.” | ||||||||
| FY 2024revised | Revenue | $63.40–$64.40bn | 2024-07-30 | — | — | — | PENDING | guidance |
| “Merck now expects its full-year sales to be between $63.4 billion and $64.4 billion, including a negative impact of foreign exchange of approximately 3 percentage points, at mid-July 2024 exchange rates.” | ||||||||
| FY 2024revised | EPS (adj.) | $8.53–$8.65 | 2024-04-25 | — | — | — | PENDING | guidance |
| “Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.53 and $8.65” | ||||||||
| FY 2024revised | Revenue | $63.10–$64.30bn | 2024-04-25 | — | — | — | PENDING | guidance |
| “Merck now expects its full-year 2024 sales to be between $63.1 billion and $64.3 billion” | ||||||||
| FY 2024 | EPS (adj.) | $8.44–$8.59 | 2024-02-01 | — | — | — | PENDING | guidance |
| “Expects Non-GAAP EPS To Be Between $8.44 and $8.59” | ||||||||
| FY 2024 | Revenue | $62.70–$64.20bn | 2024-02-01 | — | — | — | PENDING | guidance |
| “Anticipates Worldwide Sales To Be Between $62.7 Billion and $64.2 Billion” | ||||||||
| FY 2023revised | EPS (adj.) | $1.33–$1.38 | 2023-10-26 | $1.51 | +9.6% | ABOVE | guidance · result | |
| “Merck now expects its full-year non-GAAP EPS to be between $1.33 and $1.38, including a negative impact of foreign exchange of approximately 6 percentage points, at mid-October 2023 exchange rates.” | ||||||||
| FY 2023revised | Revenue | $59.70–$60.20bn | 2023-10-26 | $60.1bn | 0.0% | IN LINE | guidance · result | |
| “Merck now expects full-year sales to be between $59.7 billion and $60.2 billion, including a negative impact of foreign exchange of approximately 2 percentage points, at mid-October 2023 exchange rates.” | ||||||||
| FY 2023revised | EPS (adj.) | $2.95–$3.05 | 2023-08-01 | $1.51 | −48.0% | BELOW | guidance · result | |
| “Merck now expects its full-year non-GAAP EPS to be between $2.95 and $3.05, including a negative impact of foreign exchange of approximately 5 percentage points, at mid-July 2023 exchange rates.” | ||||||||
| FY 2023revised | Revenue | $58.60–$59.60bn | 2023-08-01 | $60.1bn | +0.9% | ABOVE | guidance · result | |
| “Merck now expects full-year sales to be between $58.6 billion and $59.6 billion, including a negative impact of foreign exchange of approximately 2 percentage points, at mid-July 2023 exchange rates.” | ||||||||
| FY 2023 | EPS (adj.) | $6.88–$7.00 | 2023-04-27 | $1.51 | −77.4% | BELOW | guidance · result | |
| “Merck is raising and narrowing its full-year 2023 non-GAAP EPS range to be between $6.88 and $7.00, including a negative impact of foreign exchange of approximately 4 percentage points, at mid-April 2023 exchange rates.” | ||||||||
| FY 2023 | EPS | $5.85–$5.97 | 2023-04-27 | $0.14 | −96.6% | BELOW | guidance · result | |
| “Merck is lowering and narrowing its full-year 2023 GAAP EPS range to be between $5.85 and $5.97.” | ||||||||
| FY 2023 | Revenue (adj.) | $57.70–$58.90bn | 2023-04-27 | — | — | — | PENDING | guidance |
| “Sales* $57.7 to $58.9 billion $57.7 to $58.9 billion” | ||||||||
| FY 2023 | Revenue | $57.70–$58.90bn | 2023-04-27 | $60.1bn | +2.1% | ABOVE | guidance · result | |
| “Merck now expects full-year 2023 sales to be between $57.7 billion and $58.9 billion, including a negative impact of foreign exchange of approximately 2 percentage points, at mid-April 2023 exchange rates.” | ||||||||
| FY 2022revised | EPS (adj.) | $7.32–$7.37 | 2022-10-27 | — | — | — | PENDING | guidance |
| “Company Raises and Narrows Expected Full-Year 2022 Non-GAAP EPS To Be Between $7.32 and $7.37” | ||||||||
| FY 2022revised | EPS | $5.68–$5.73 | 2022-10-27 | — | — | — | PENDING | guidance |
| “Company Lowers Expected Full-Year 2022 GAAP EPS To Be Between $5.68 and $5.73” | ||||||||
| FY 2022revised | Revenue | $58.50–$59.00bn | 2022-10-27 | — | — | — | PENDING | guidance |
| “Company Raises and Narrows Expected Full-Year 2022 Worldwide Sales To Be Between $58.5 Billion and $59.0 Billion” | ||||||||
| FY 2022revised | EPS (adj.) | $7.25–$7.35 | 2022-07-28 | — | — | — | PENDING | guidance |
| “Merck is narrowing its expected full-year 2022 non-GAAP EPS range to be between $7.25 and $7.35” | ||||||||
| FY 2022revised | EPS | $5.89–$5.99 | 2022-07-28 | — | — | — | PENDING | guidance |
| “Merck expects its estimated full-year 2022 GAAP EPS to be between $5.89 and $5.99.” | ||||||||
| FY 2022revised | Revenue (adj.) | $57.50–$58.50bn | 2022-07-28 | — | — | — | PENDING | guidance |
| “Sales $57.5 to $58.5 billion $57.5 to $58.5 billion*” | ||||||||
| FY 2022revised | Revenue | $57.50–$58.50bn | 2022-07-28 | — | — | — | PENDING | guidance |
| “Company Raises and Narrows Expected Full-Year 2022 Worldwide Sales Range To Be Between $57.5 Billion and $58.5 Billion” | ||||||||
| FY 2022revised | EPS (adj.) | $7.24–$7.36 | 2022-04-28 | — | — | — | PENDING | guidance |
| “Merck is raising and narrowing its full-year 2022 non-GAAP EPS range to be between $7.24 and $7.36, including a negative impact from foreign exchange of approximately 2%, or $0.11, at mid-April 2022 exchange rates.” | ||||||||
| FY 2022revised | EPS | $5.90–$6.02 | 2022-04-28 | — | — | — | PENDING | guidance |
| “Merck is raising and narrowing its full-year 2022 GAAP EPS range to be between $5.90 and $6.02.” | ||||||||
| FY 2022 | Revenue (adj.) | $56.90–$58.10bn | 2022-04-28 | — | — | — | PENDING | guidance |
| “Sales $56.9 to $58.1 billion $56.9 to $58.1 billion*” | ||||||||
| FY 2022revised | Revenue | $56.90–$58.10bn | 2022-04-28 | — | — | — | PENDING | guidance |
| “Company Raises and Narrows Full-Year 2022 Worldwide Sales To Be Between $56.9 Billion and $58.1 Billion, Reflecting Projected Full-Year Growth of 17% to 19%” | ||||||||
| FY 2022 | EPS (adj.) | $7.12–$7.27 | 2022-02-03 | — | — | — | PENDING | guidance |
| “Merck expects full-year 2022 non-GAAP EPS to be between $7.12 and $7.27, including a negative impact from foreign exchange of approximately 1%.” | ||||||||
| FY 2022 | EPS | $5.76–$5.91 | 2022-02-03 | — | — | — | PENDING | guidance |
| “Merck expects full-year 2022 GAAP EPS to be between $5.76 and $5.91.” | ||||||||
| FY 2022 | Revenue | $56.10–$57.60bn | 2022-02-03 | — | — | — | PENDING | guidance |
| “Merck anticipates full-year 2022 revenue to be between $56.1 billion and $57.6 billion, including a negative impact from foreign exchange of approximately 2% at mid-January 2022 exchange rates.” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.
Coverage universe: S&P 100. This is a factual record of what a company forecast and what it then reported. It is not investment advice, and it is not a view on the company’s prospects — we publish the measurement and draw no conclusion from it.